Development of novel thiazolidine-2,4-dione derivatives as PPAR-γ agonists through design, synthesis, computational docking, MD simulation, and comprehensive <i>in vitro</i> and <i>in vivo</i> evaluation
Mahendra Gowdru Srinivasa, B. C. Revanasiddappa, Ashwini Prabhu, Vinitha Rani, Sudeep D. Ghate, B. R. Prashantha Kumar
Abstract
blood glucose-lowering potential by using a dexamethasone-induced diabetic rat model. All the compounds showed a hypoglycaemic effect of 108.04 ± 4.39, 112.55 ± 6.10, and 117.48 ± 43.93, respectively, along with pioglitazone (153.93 ± 4.61) compared to the diabetic control. Additionally, all the compounds significantly reduced AST and ALT levels and did not cause liver damage.
Topics & Concepts
ThiazolidineDocking (animal)In vivoThiazolidinedionePeroxisome proliferatorIn vitroPeroxisome proliferator-activated receptorChemistryPharmacologyReceptorCombinatorial chemistryStereochemistryBiochemistryMedicineBiologyEndocrinologyBiotechnologyDiabetes mellitusType 2 diabetesNursingPeroxisome Proliferator-Activated ReceptorsMetabolism, Diabetes, and CancerDiabetes Treatment and Management